(NASDAQ: MGNX) Macrogenics's forecast annual revenue growth rate of -16.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.27%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.74%.
Macrogenics's revenue in 2025 is $127,625,000.On average, 9 Wall Street analysts forecast MGNX's revenue for 2026 to be $3,977,886,268, with the lowest MGNX revenue forecast at $681,926,975, and the highest MGNX revenue forecast at $7,744,742,073. On average, 6 Wall Street analysts forecast MGNX's revenue for 2027 to be $4,032,731,415, with the lowest MGNX revenue forecast at $3,719,601,682, and the highest MGNX revenue forecast at $4,317,394,809.
In 2028, MGNX is forecast to generate $4,859,583,687 in revenue, with the lowest revenue forecast at $3,719,601,682 and the highest revenue forecast at $6,019,808,422.